InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.062

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$19 Audited Financial Statements 27 Sep 2024 1:21PM $0.100 $0.062 fallen by 38%
$19 Appendix 4G and Corporate Governance Statement 27 Sep 2024 1:18PM $0.100 $0.062 fallen by 38%
$19 Proposed issue of securities - NOX 27 Sep 2024 11:28AM $0.100 $0.062 fallen by 38%
$19 New funding from sophisticated investors 27 Sep 2024 11:26AM $0.100 $0.062 fallen by 38%
$19 Completes SOF-SKN formulation as clinical trial approaches 17 Sep 2024 8:31AM $0.100 $0.062 fallen by 38%
$19 Advanced funding secured ahead of R&D rebate 6 Sep 2024 8:23AM $0.125 $0.062 fallen by 50.40%
$19 Significant results from new brain cancer drugs 3 Sep 2024 8:16AM $0.105 $0.062 fallen by 40.95%
$19 Ceasing to be a substantial holder - Goodridge 30 Aug 2024 8:55AM $0.093 $0.062 fallen by 33.33%
$19 Appendix 4E Preliminary Final Report 29 Aug 2024 8:07AM $0.105 $0.062 fallen by 40.95%
$19 Noxopharm Targets Clinical Trial for First-in-Class Drug 19 Aug 2024 10:01AM $0.082 $0.062 fallen by 24.39%
$19 Significant CRO-67 Results in Pancreatic Cancer Studies 14 Aug 2024 10:40AM $0.084 $0.062 fallen by 26.19%
$19 June 2024 Quarterly Activities Report and Appendix 4C 23 Jul 2024 8:19AM $0.072 $0.062 fallen by 13.89%
$19 Noxopharm joins global Alliance for mRNA Medicines 28 May 2024 8:25AM $0.075 $0.062 fallen by 17.33%
$19 Milestone reached as SOF-SKN progresses to next level 14 May 2024 8:20AM $0.063 $0.062 fallen by 1.59%
$19 March 2024 Quarterly Activities Report and Appendix 4C 29 Apr 2024 8:29AM $0.064 $0.062 fallen by 3.13%
$19 Tour de Cure Grant for Brain Cancer Research 4 Apr 2024 8:23AM $0.065 $0.062 fallen by 4.62%
$19 Appendix 4D and Half Year 2024 Financial Report 27 Feb 2024 8:01AM $0.073 $0.062 fallen by 15.07%
$19 Noxopharm extends Hudson Institute strategic partnership 13 Feb 2024 8:06AM $0.060 $0.062 risen by 3.33%
$19 December 2023 Quarterly Activities Report and Appendix 4C 22 Jan 2024 12:31PM $0.069 $0.062 fallen by 10.14%
$19 Change of Director's Interest Notice - GM 18 Dec 2023 10:23AM $0.085 $0.062 fallen by 27.06%
$19 Notification of cessation of securities - NOX 18 Dec 2023 8:18AM $0.085 $0.062 fallen by 27.06%
$19 Results of Meeting 16 Nov 2023 4:10PM $0.140 $0.062 fallen by 55.71%
$19 Noxopharm Enhances Cash Position via R&D Rebate 16 Nov 2023 8:36AM $0.125 $0.062 fallen by 50.40%
$19 Noxopharm 2023 AGM Corporate Presentation 16 Nov 2023 8:29AM $0.125 $0.062 fallen by 50.40%
$19 Noxopharm 2023 AGM Chair Address 16 Nov 2023 8:20AM $0.125 $0.062 fallen by 50.40%

101 - 125 of 800 results

Page 5 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.